Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 10/20 | 0.56 |
| ▸ | HTR2A | P28223 | 5/20 | 0.50 |
| ▸ | HRH1 | P35367 | 2/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27854231 | 0.86 | TAAR1 (0.41) | TAAR1HTR2AHRH1CYP2A6SMN1; SMN2 | |
| SCHEMBL5869932 | 0.84 | TAAR1 (0.35) | TAAR1HTR2A | |
| SCHEMBL224549 | 0.81 | TAAR1 (0.70) | TAAR1HTR2AHRH1CYP2A6SMN1; SMN2 | |
| SCHEMBL1533499 | 0.80 | TAAR1 (0.39) | TAAR1HTR2A | |
| SCHEMBL231454 | 0.79 | — | — | |
| SCHEMBL10719547 | 0.79 | LIPG (0.34) | TAAR1HTR2AMPO | |
| SCHEMBL1606781 | 0.77 | TAAR1 (0.31) | TAAR1 | |
| SCHEMBL27871136 | 0.77 | PNMT (0.48) | TAAR1HTR2ACYP2A6LOXL2 | |
| SCHEMBL7764797 | 0.76 | TAAR1 (0.37) | TAAR1 | |
| SCHEMBL135178 | 0.75 | LIPG (0.36) | TAAR1ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104869992-A | N-substituted indazole sulfonamide compounds with selective activity for voltage-gated sodium channels | MERCK SHARP & DOHME | 2015-08-26 | — | — | CN | claimed |
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-07 | — | — | US | claimed |
| WO-2010014798-A2 | PYRIMIDOTRIAZINEDIONES AND PYRIMIDOPYRIMIDINEDIONES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-02-04 | — | — | WO | claimed |
| US-6686373-B2 | ANALGESICS; ANTIINFLAMMATORY AGENT | WARNER-LAMBERT COMPANY LLC | 2004-02-03 | — | — | US | claimed |
| US-20030130277-A1 | Pyrazoloquinolinone derivatives as protein kinase C inhibitors | KAWAMURA KIYOSHI (JP) | 2003-07-10 | — | — | US | claimed |
| EP-1310498-A2 | Pyrazoloquinolinone derivatives as protein kinase C inhibitors | PFIZER INC. (US) | 2003-05-14 | — | — | EP | claimed |
| US-20230181524-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| EP-4129282-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-02-08 | — | — | EP | disclosed |
| US-20120115817-A1 | PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES | EMS S.A. (BR) | 2012-05-10 | — | — | US | disclosed |
| EP-2418200-A1 | PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF- MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES | EMS S. A. (BR) | 2012-02-15 | — | — | EP | disclosed |
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-07 | — | — | US | disclosed |
| WO-2010014798-A2 | PYRIMIDOTRIAZINEDIONES AND PYRIMIDOPYRIMIDINEDIONES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-02-04 | — | — | WO | disclosed |
| US-6686373-B2 | ANALGESICS; ANTIINFLAMMATORY AGENT | WARNER-LAMBERT COMPANY LLC | 2004-02-03 | — | — | US | disclosed |
| US-20030130277-A1 | Pyrazoloquinolinone derivatives as protein kinase C inhibitors | KAWAMURA KIYOSHI (JP) | 2003-07-10 | — | — | US | disclosed |
| EP-1310498-A2 | Pyrazoloquinolinone derivatives as protein kinase C inhibitors | PFIZER INC. (US) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130277-A1 | Pyrazoloquinolinone derivatives as protein kinase C inhibitors | PRKCB, PRKCA, PRKCG | TAAR1 2269/4885HTR2A 1518/4885HRH1 242/4885 |
| US-20230181524-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | TCF4, TCF7L2, CTNNB1 | TAAR1 4697/4885HTR2A 2864/4885HRH1 2972/4885 |
| US-20120115817-A1 | PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES | TNF, PER2, CRY1 | TAAR1 2640/4885HTR2A 1622/4885HRH1 637/4885 |
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | DPYD, TYMP, DHFR | TAAR1 4036/4885HTR2A 3556/4885HRH1 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.